PMID- 31695404
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Systemic inflammation score in locally advanced rectal cancer patients following 
      total mesorectal excision.
PG  - 6617-6622
LID - 10.2147/OTT.S213720 [doi]
AB  - OBJECTIVE: The objective of the study was to evaluate whether any association 
      exists between systemic inflammation score (SIS) and adverse events (AEs) and 
      survival of locally advanced rectal cancer patients treated with total mesorectal 
      excision (TME) followed by adjuvant chemoradiotherapy. PATIENTS AND METHODS: All 
      of the 109 rectal cancer patients recruited between May 2008 and June 2015 were 
      treated with TME followed by adjuvant chemoradiotherapy. The prognostic ability 
      of SIS for overall survival (OS) was calculated by the receiver operating 
      characteristic (ROC) curves. RESULTS: According to the classification of the SIS, 
      22 (20.2%), 59 (54.1%) and 28 (25.7%) patients were classified as a score of 2, 1 
      and 0, respectively. With an area under the curve (AUC) of 0.616, the SIS score 
      of 1 was defined as the optimal cut-off value. Therefore, we divided the patients 
      into the SIS-low group (SIS score of 1 or 0, n=87) and SIS-high group (SIS score 
      of 2, n=22). Multivariate analysis indicated that SIS was associated with OS (HR 
      0.390, 95% CI 0.186-0.817, P=0.012). The 5-year OS rate in patients without 
      adjuvant chemotherapy was lower than the patients with adjuvant chemotherapy 
      (53.3% vs 75.8%, P=0.010). Multivariate analysis showed that adjuvant 
      chemotherapy was associated with OS (HR 0.217, 95% CI 0.089-0.529, P=0.001). A 
      marginal statistically significant difference was observed in terms of leukopenia 
      during adjuvant chemoradiotherapy between the SIS-low group and the SIS-high 
      group (P=0.05). CONCLUSION: These results suggest that SIS might serve as an 
      independent biomarker for predicting AEs and prognosis in locally advanced rectal 
      cancer treated with TME followed by adjuvant chemoradiotherapy. Strengthening 
      treatment may be administered to locally advanced rectal cancer with high SIS 
      score obtained before adjuvant chemoradiotherapy.
CI  - (c) 2019 Feng et al.
FAU - Feng, Yanru
AU  - Feng Y
AD  - Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, 
      Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
FAU - Liu, Luying
AU  - Liu L
AD  - Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, 
      Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
FAU - Zhu, Yuan
AU  - Zhu Y
AD  - Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, 
      Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190819
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6707432
OTO - NOTNLM
OT  - SIS
OT  - acute adverse event
OT  - chemoradiotherapy
OT  - rectal cancer
OT  - survival
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/11/07 06:00
MHDA- 2019/11/07 06:01
PMCR- 2019/08/19
CRDT- 2019/11/08 06:00
PHST- 2019/04/28 00:00 [received]
PHST- 2019/07/30 00:00 [accepted]
PHST- 2019/11/08 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2019/11/07 06:01 [medline]
PHST- 2019/08/19 00:00 [pmc-release]
AID - 213720 [pii]
AID - 10.2147/OTT.S213720 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Aug 19;12:6617-6622. doi: 10.2147/OTT.S213720. 
      eCollection 2019.